The global preeclampsia diagnostics market size reached USD 1,000 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,240 Million by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The rising prevalence of preeclampsia, the growing awareness among individuals regarding the importance of health, and the increasing healthcare expenditure represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 1,000 Million |
Market Forecast in 2033 | USD 1,240 Million |
Market Growth Rate 2025-2033 | 2.9% |
Preeclampsia, also known as toxemia, is a rapidly progressive pregnancy complication characterized by hypertension, proteinuria, high blood pressure, excessive protein in the urine of the mother, and damage to organs, typically the liver and kidneys. It can result in serious consequences for the mother and baby, including premature birth, low birth weight, and in severe cases, maternal and fetal death. There are various methods for diagnosing preeclampsia, which is typically used in combination. This involves a range of tests and procedures to identify the condition, assess its severity, and monitor the health of the mother and baby. Some of the common diagnostic methods are blood pressure monitoring, urine tests, and blood tests to measure certain biomarkers, and ultrasound imaging to evaluate fetal growth and well-being. They are conducted to diagnose and manage preeclampsia and reduce the risk of complications for both the mother and baby. Owing to these benefits, preeclampsia diagnostic methods are widely adopted across hospitals, nursing homes, and diagnostic centers.
The market is primarily driven by the growing prevalence of preeclampsia. Preeclampsia is a common pregnancy complication, which affects approximately 2-8% of all pregnancies worldwide. In addition, the rising awareness among pregnant women and healthcare providers about the importance of health and wellness is escalating the demand for preeclampsia diagnostics. Besides this, various technological advancements, such as the introduction of biomarker tests and imaging techniques, are driving the development of new and more accurate preeclampsia diagnostics. Along with this, there have been recent advances in management strategies for patients with hypertensive disorders of pregnancy. This, coupled with the rising healthcare expenditure globally and the increasing focus on improving maternal and fetal health outcomes, is positively influencing the market growth. Moreover, governments and regulatory bodies of various countries are taking steps to improve maternal and fetal health by investing in research and the development (R&D) of new diagnostics for preeclampsia. Along with this, the market is propelled by the launch of point-of-care tests for identifying preeclampsia at an earlier stage. Furthermore, the increasing collaborations and mergers and acquisitions (M&As) among key market players, the rising disposable incomes, and the growing number of hospitals, especially in developing economies, are other factors creating a positive market outlook across the globe.
IMARC Group provides an analysis of the key trends in each segment of the global preeclampsia diagnostics market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on test type, product, and end-user.
Test Type Insights:
The report has provided a detailed breakup and analysis of the preeclampsia diagnostics market based on the test type. This includes blood tests and urine analysis. According to the report, blood tests represented the largest segment.
Product Insights:
A detailed breakup and analysis of the preeclampsia diagnostics market based on the product has also been provided in the report. This includes instruments and consumables. According to the report, consumables accounted for the largest market share.
End-User Insights:
The report has provided a detailed breakup and analysis of the preeclampsia diagnostics market based on the end-user. This includes hospitals, specialty clinics, diagnostic centers, and others. According to the report, diagnostic centers represented the largest segment.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for preeclampsia diagnostics. Some of the factors driving the North America preeclampsia diagnostics market included the rising awareness among individuals, increasing healthcare expenditure, and various technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global preeclampsia diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Diabetomics Inc., DRG Instruments GmbH, F. Hoffmann-La Roche Ltd., Metabolomic Diagnostics Limited, MOMM Diagnostics, PerkinElmer Inc., Sera Prognostics, Siemens Healthineers AG, Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report | Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
|
Test Types Covered | Blood Tests, Urine Analysis |
Products Covered | Instruments, Consumables |
End Users Covered | Hospitals, Specialty Clinics, Diagnostic Centers, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Diabetomics Inc., DRG Instruments GmbH, F. Hoffmann-La Roche Ltd., Metabolomic Diagnostics Limited, MOMM Diagnostics, PerkinElmer Inc., Sera Prognostics, Siemens Healthineers AG, Thermo Fisher Scientific Inc., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |